Kalohexis Doses First Patients in 710GO Phase I Trial for Obesity

Why It Matters

First‑in‑human data could confirm a novel metabolic pathway that delivers durable weight loss with fewer side effects, expanding options beyond current GLP‑1 therapies.

Key Takeaways

• First human dosing of oral MC3R/MC4R agonist 710GO.
• Phase I trial enrolls ~100 obese volunteers in Australia.
• Preclinical primates lost 11.7% body weight over 13 weeks.
• 710GO showed minimal gastrointestinal and cardiovascular adverse events.
• Potential to combine with semaglutide for greater weight loss.

Pulse Analysis

Obesity remains a global health crisis, and the pharmaceutical landscape is dominated by injectable GLP‑1 receptor agonists such as semaglutide and tirzepatide. While effective, these drugs often trigger gastrointestinal discomfort and can lead to rapid weight regain once therapy stops. Kalohexis is targeting the melanocortin system—a central regulator of energy balance—by developing 710GO, an oral peptide that simultaneously activates MC3R and MC4R. This dual‑receptor approach promises a more physiological reset of metabolic set points, potentially delivering steadier, longer‑lasting weight loss without the tolerability issues that have limited broader adoption of existing injectables.

The Phase I trial in Australia follows a rigorous design: a randomized, double‑blind, placebo‑controlled framework that evaluates single‑ascending doses, 28‑day multiple‑ascending doses, and food‑effect interactions. Recruiting about 100 participants who are obese or merely overweight, the study will generate early pharmacodynamic and pharmacokinetic data, as well as preliminary efficacy signals and safety readouts. By measuring changes in body weight, fat mass, lean mass, and metabolic biomarkers, Kalohexis aims to demonstrate that 710GO can achieve meaningful weight reduction while preserving muscle and avoiding the nausea, vomiting, or cardiovascular concerns seen with GLP‑1 agents.

If the early data confirm the preclinical promise, 710GO could reshape the anti‑obesity market. Its oral formulation simplifies administration, improving patient adherence, and its mechanism may allow seamless combination with existing GLP‑1 drugs to amplify outcomes. Investors are watching closely, as a successful trial could position Kalohexis for fast‑track regulatory pathways and partnerships with major pharma firms seeking to diversify their obesity pipelines. Ultimately, a new, well‑tolerated oral therapy could broaden access to effective weight‑loss treatment, addressing a critical unmet need in both clinical practice and public health.